Cite
First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials.
MLA
Cabibbo, Giuseppe, et al. “First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials.” Liver Cancer (2235-1795), vol. 11, no. 1, Jan. 2022, pp. 75–84. EBSCOhost, https://doi.org/10.1159/000520278.
APA
Cabibbo, G., Reig, M., Celsa, C., Torres, F., Battaglia, S., Enea, M., Rizzo, G. E. M., Petta, S., Calvaruso, V., Di Marco, V., Craxì, A., Singal, A. G., Bruix, J., & Cammà, C. (2022). First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials. Liver Cancer (2235-1795), 11(1), 75–84. https://doi.org/10.1159/000520278
Chicago
Cabibbo, Giuseppe, Maria Reig, Ciro Celsa, Ferran Torres, Salvatore Battaglia, Marco Enea, Giacomo Emanuele Maria Rizzo, et al. 2022. “First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials.” Liver Cancer (2235-1795) 11 (1): 75–84. doi:10.1159/000520278.